The reduction in price target could have a mixed impact on Altimmune's stock price. On one hand, the lowered price target might suggest a tempered outlook, potentially leading to short-term negative sentiment among investors. On the other hand, maintaining a Buy rating indicates a positive view on the company's fundamentals and future prospects. The net effect on the stock price in the short term is uncertain, hence a neutral score.